E. Kralidis

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

H. Hawle, M. Fehr, K. Ribi, 2022, Endocrine oncology.

Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.

H. Friess, M. Büchler, S. Aebi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

A. Giobbie-Hurder, P. Neven, R. Gelber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

R. Gelber, H. Gómez, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

D. Katsaros, L. Cavanna, I. Meinhold-Heerlein, 2023, British Journal of Cancer.